Company intelligence / Profile preview
Atropos Therapeutics
Houston, Texas, United Statesatroposthera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Preclinical-stage biotech developing therapies targeting senescent cell formation for aging-related diseases and cancer; one preclinical program (PM-43I) in asthma and atopic dermatitis.
- Therapeutic areas
- OtherOncologyPulmonologyDermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Atomwise (joint venture for senescence modulating small molecules in cancer)The University of Texas MD Anderson Cancer Center (originator for PM-43I)
Beyond the preview
Go deeper on Atropos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atropos Therapeutics.